Breaking News Instant updates and real-time market news.

TGT

Target

$103.11

17.54 (20.50%)

09:06
08/22/19
08/22
09:06
08/22/19
09:06

Target price target raised to $112 from $90 at Credit Suisse

Credit Suisse analyst Seth Sigman raised his price target for Target to $112 from $90 as its "stronger" Q2 results continue to support his positive view, centered on its improving competitive position and ability to take share across a number of core categories through an improving omni-channel offering, compelling value proposition and differentiated assortment. The analyst reiterates an Outperform rating on the shares.

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

TGT Target
$103.11

17.54 (20.50%)

08/22/19
TLSY
08/22/19
NO CHANGE
Target $115
TLSY
Outperform
Target price target raised to $115 from $92 at Telsey Advisory
Telsey Advisory analyst Joseph Feldman raised his price target on Target to $115 and kept his Outperform rating after its "solid" Q2 results. The analyst says the company's transformation initiatives with merchandising, operations, and omni-channel sales is resonating well with consumers while driving the company's market share gains. Feldman adds that Target's guidance may prove conservative given its continued business momentum.
08/22/19
KEYB
08/22/19
NO CHANGE
Target $120
KEYB
Overweight
Target price target raised to $120 from $110 at KeyBanc
KeyBanc analyst Edward Yruma raised his price target for Target to $120 from $110 as the company's "strong" Q2 performance points to share gains driven by "strong" merchandising and store experience, as well as ongoing improvements to e-commerce. The analyst highlighted Target as one of his focus names in his 2019 outlook, and believes that momentum will continue into the second half of the year. Yruma reiterates an Overweight rating on the shares.
08/22/19
COWN
08/22/19
NO CHANGE
Target $120
COWN
Outperform
Target valuation remains modest, says Cowen
Cowen analyst Oliver Chen raised his price target on Target to $120 from $100 following Q2 results. The analyst cited its own brand newness and execution combined with in-store talent which drove impressive cops. He noted guidance was raised and believes valuation remains modest relative to the opportunities ahead. Chen reiterated his Outperform rating on Target shares.
08/22/19
BUCK
08/22/19
NO CHANGE
Target $61
BUCK
Buy
Target price target raised to $117 from $102 at Buckingham
Buckingham analyst Bob Summers raised his price target for Target to $117 from $102 and reiterated a Buy rating following the company's quarterly results. In a research note to investors, Summers says he believes Target continues to distance itself from most of its competitors, as evidenced by its third consecutive quarter of driving EPS upside and margin expansion with comparable store sales and e-commerce delivering strong results over at least the last six quarters, and feels this puts Target in a more elite group of retailers. He believes the stock's valuation will continue to re-rate, and says the ability to "comp the comp" and no apparent intermediate-term threat of a major earnings reset will also improve valuation.

TODAY'S FREE FLY STORIES

XLRN

Acceleron

$44.67

0.75 (1.71%)

06:43
09/17/19
09/17
06:43
09/17/19
06:43
Recommendations
Acceleron analyst commentary  »

Acceleron should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 04

    Dec

  • 04

    Apr

CBMG

Cellular Biomedicine

$14.75

-0.16 (-1.07%)

06:43
09/17/19
09/17
06:43
09/17/19
06:43
Initiation
Cellular Biomedicine initiated  »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGOV

NIC Inc.

$21.79

0.05 (0.23%)

06:40
09/17/19
09/17
06:40
09/17/19
06:40
Downgrade
NIC Inc. rating change  »

NIC Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

SPLK

Splunk

$114.87

1.19 (1.05%)

06:39
09/17/19
09/17
06:39
09/17/19
06:39
Upgrade
JPMorgan upgrades Splunk to Overweight after 19% selloff since late July »

JPMorgan analyst Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

OLN

Olin

$19.27

0.46 (2.45%)

06:38
09/17/19
09/17
06:38
09/17/19
06:38
Conference/Events
Olin management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

  • 23

    Sep

CBMG

Cellular Biomedicine

$14.75

-0.16 (-1.07%)

06:38
09/17/19
09/17
06:38
09/17/19
06:38
Initiation
Cellular Biomedicine initiated  »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXNX

Axonics

$30.13

-0.77 (-2.49%)

06:37
09/17/19
09/17
06:37
09/17/19
06:37
Initiation
Axonics initiated  »

Axonics initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HXGBY

Hexagon AB

$0.00

(0.00%)

06:36
09/17/19
09/17
06:36
09/17/19
06:36
Conference/Events
Hexagon AB management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

APOG

Apogee Enterprises

$41.18

-0.38 (-0.91%)

06:34
09/17/19
09/17
06:34
09/17/19
06:34
Earnings
Apogee Enterprises reaffirms FY20 EPS view $3.00-$3.20, consensus $3.05 »

Reaffirms FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 23

    Sep

MDGL

Madrigal Pharmaceuticals

$99.50

4.89 (5.17%)

06:34
09/17/19
09/17
06:34
09/17/19
06:34
Recommendations
Madrigal Pharmaceuticals analyst commentary  »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBF

SoftBank

$0.00

(0.00%)

, UBER

Uber

$34.42

1.18 (3.55%)

06:32
09/17/19
09/17
06:32
09/17/19
06:32
Periodicals
SoftBank backers consider slashing committments to Vision Fund, Bloomberg says »

The biggest backers of…

SFTBF

SoftBank

$0.00

(0.00%)

UBER

Uber

$34.42

1.18 (3.55%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSI

Stage Stores

$0.85

0.0298 (3.63%)

06:32
09/17/19
09/17
06:32
09/17/19
06:32
Hot Stocks
Stage Stores announces plans to convert substantially all stores to off-price »

Stage Stores announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APOG

Apogee Enterprises

$41.18

-0.38 (-0.91%)

06:31
09/17/19
09/17
06:31
09/17/19
06:31
Earnings
Apogee Enterprises reports Q2 EPS 72, consensus 64c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

  • 23

    Sep

IAC

IAC

$229.23

1.71 (0.75%)

06:30
09/17/19
09/17
06:30
09/17/19
06:30
Initiation
IAC initiated  »

IAC initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

AMRN

Amarin

$17.26

0.55 (3.29%)

, MDCO

The Medicines Co.

$48.74

0.99 (2.07%)

06:29
09/17/19
09/17
06:29
09/17/19
06:29
Recommendations
Citi puts Amarin and Sarepta on top five SMid cap biotech pick list »

Citi analyst Joel Beatty…

AMRN

Amarin

$17.26

0.55 (3.29%)

MDCO

The Medicines Co.

$48.74

0.99 (2.07%)

NERV

Minerva

$8.12

0.12 (1.50%)

SRPT

Sarepta

$87.02

1.01 (1.17%)

ELOX

Eloxx Pharmaceuticals

$6.45

0.1 (1.57%)

NGM

NGM Biopharmaceuticals

$15.85

-0.15 (-0.94%)

PTCT

PTC Therapeutics

$42.99

0.16 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MRVL

Marvell

$25.39

-0.46 (-1.78%)

06:28
09/17/19
09/17
06:28
09/17/19
06:28
Hot Stocks
SEC says Marvell Technology to pay $5.5M to settle disclosure-related charges »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANGI

Angi Homeservices

$7.91

-0.075 (-0.94%)

, GOOG

Alphabet

$1,231.36

-8.24 (-0.66%)

06:28
09/17/19
09/17
06:28
09/17/19
06:28
Initiation
Angi Homeservices, Alphabet, Alphabet Class A initiated  »

Angi Homeservices…

ANGI

Angi Homeservices

$7.91

-0.075 (-0.94%)

GOOG

Alphabet

$1,231.36

-8.24 (-0.66%)

GOOGL

Alphabet Class A

$1,231.45

-8.68 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Oct

MTCH

Match Group

$76.70

1.74 (2.32%)

06:26
09/17/19
09/17
06:26
09/17/19
06:26
Initiation
Match Group initiated  »

Match Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPL

LG Display

$6.42

-0.01 (-0.16%)

, AAPL

Apple

$219.88

1.17 (0.53%)

06:26
09/17/19
09/17
06:26
09/17/19
06:26
Periodicals
LG Display plans voluntary redundancy program, Reuters reports »

LG Display (LPL) plans to…

LPL

LG Display

$6.42

-0.01 (-0.16%)

AAPL

Apple

$219.88

1.17 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOLD

Barrick Gold

$17.11

-0.11 (-0.64%)

06:24
09/17/19
09/17
06:24
09/17/19
06:24
Hot Stocks
Barrick Gold says Acacia Mining scheme becomes effective »

On July 19, the Boards of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXRP

Lexaria Bioscience

$0.00

(0.00%)

06:22
09/17/19
09/17
06:22
09/17/19
06:22
Hot Stocks
Lexaria Bioscience says TurboCBD capsule study results published »

Lexaria Bioscience…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IFNNY

Infineon

$0.00

(0.00%)

, SNPS

Synopsys

$133.17

-1.45 (-1.08%)

06:20
09/17/19
09/17
06:20
09/17/19
06:20
Hot Stocks
Infineon enters collaboration with Synopsys »

Infineon Technologies AG…

IFNNY

Infineon

$0.00

(0.00%)

SNPS

Synopsys

$133.17

-1.45 (-1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

EADSY

Airbus

$0.00

(0.00%)

06:19
09/17/19
09/17
06:19
09/17/19
06:19
Periodicals
Airbus doesn't see major 2019 impact from tariffs, Reuters reports »

Possible U.S. tariffs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVER

EverQuote

$24.73

2.33 (10.40%)

06:18
09/17/19
09/17
06:18
09/17/19
06:18
Downgrade
EverQuote rating change  »

EverQuote downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

$49.04

-0.45 (-0.91%)

06:15
09/17/19
09/17
06:15
09/17/19
06:15
Recommendations
D.R. Horton analyst commentary  »

D.R. Horton price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.